Novartis Investigative Site

Ulyanovsk 432063

1 studies enrolling now · 9 studies all time

What they study most

Acute Heart Failure, Ankylosing Spondylitis, Asthma, Autoimmunity, Inflammation, Cardiovascular Disease and Lipoprotein(a), Proliferative Diabetic Retinopathy

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy — Completed
• Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma — Stopped early
• Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients — Stopped early
• Global Non-interventional Heart Failure Disease Registry — Stopped early